Clinical Trial

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis LUCENT 2

Study Status:

Contact Information:

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose

The purpose of this study is to evaluate the safety and efficacy of mirikizumab in maintaining remission at Week 40 in patients who completed the 12-week iduction study 16T-MC-AMAN.


Principal Investigator Sriramachandra Badiga, MD
Type of Trial Prospective/Interventional